Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
In addition to Canaccord Genuity, Dexcom also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Barclays reiterated a Sell rating on Dexcom (NASDAQ: ...
Bernstein analyst Lee Hambright maintained a Buy rating on Dexcom today and set a price target of $86.00. According to TipRanks, Hambright is a 4-star analyst with an average return of 8.1% and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback